Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Rating of “Buy” by Analysts

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have been assigned an average recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $10.00.

A number of equities research analysts have weighed in on the stock. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Piper Sandler cut their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, December 30th. Finally, Chardan Capital cut their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th.

Century Therapeutics Price Performance

Shares of NASDAQ IPSC opened at $0.77 on Friday. Century Therapeutics has a 1 year low of $0.68 and a 1 year high of $5.51. The company’s 50-day moving average is $0.98 and its 200 day moving average is $1.35. The stock has a market capitalization of $65.86 million, a P/E ratio of -0.42 and a beta of 1.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Century Therapeutics in the third quarter worth approximately $27,000. Geode Capital Management LLC lifted its position in Century Therapeutics by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after purchasing an additional 23,413 shares during the period. Jane Street Group LLC lifted its position in Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the period. Marshall Wace LLP bought a new position in Century Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Barclays PLC lifted its position in Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after purchasing an additional 45,797 shares during the period. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.